RxDoctor Payments Data

Joanne Chien, NP

Nurse Practitioner · Stanford, CANPI 1629399449

Payments from drug & device makers

$4,824in general payments, 2019–2025

Across 31 payments — averaging $155.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Seagen Inc.$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Janssen Scientific Affairs, LLC$970
  • Gilead$190
  • Eisai Inc.$123
  • Sanofi$122
  • plus $150 from 5 others

What the payments were for

  • Consulting fees$2,43450%
  • Food & beverage$2,19245%
  • Education$1984%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,824 in reported general payments places this provider in the 90th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$102,861
Medicare patients
284
Services billed
750

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabometyxCabozantinib S-Malate96$1,694,589
FotivdaTivozanib Hcl24$666,129
XtandiEnzalutamide44$601,114
NubeqaDarolutamide36$451,379
LenvimaLenvatinib Mesylate18$432,570
Abiraterone Acetate400$339,506
WeliregBelzutifan21$319,768
ErleadaApalutamide20$287,001
OrgovyxRelugolix35$93,412
Everolimus12$81,391
EliquisApixaban60$38,469
MyrbetriqMirabegron14$6,421
Entecavir19$3,254
Prednisone346$2,073
Megestrol Acetate20$1,619

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerNubeqa$25$451,37936 claims
Eisai Inc.Lenvima$123$432,57018 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$970$339,506400 claims
MerckWelireg$17$319,76821 claims
PfizerEliquis$27$38,46960 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →